SCHEMBL23950340

SCHEMBL23950340

NNC(=O)c1cc(I)n[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 5/20 0.53
MAPT P10636 4/20 0.49
ALDH1A1 P00352 4/20 0.49
LMNA P02545 1/20 0.49
GAA P10253 5/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 3/20 0.39
MAPK1 P28482 1/20 0.39
CHEK1 O14757 1/20 0.37
RET P07949 1/20 0.37
PDGFRB P09619 1/20 0.37
PIM1 P11309 1/20 0.37
PDGFRA P16234 1/20 0.37
GSK3B P49841 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25751918 0.78
SCHEMBL2824535 0.77 ALPL (0.53) ALPLMAPTALDH1A1LMNAGAA
SCHEMBL1815054 0.73 ALPL (0.49) ALPLMAPTALDH1A1LMNAGAA
SCHEMBL2558066 0.72 CHEK1 (0.71) MAPTALDH1A1LMNAGAAMEN1
SCHEMBL23950171 0.70 ALPL (0.50) ALPLMAPTALDH1A1LMNAGAA
SCHEMBL28037744 0.69 ALDH1A1 (0.47) ALPLMAPTALDH1A1LMNAGAA
SCHEMBL23950158 0.69 ALOX15 (0.51) ALPLMAPTALDH1A1LMNAGAA
SCHEMBL23950177 0.68 ALPL (0.48) ALPLMAPTALDH1A1LMNAGAA
SCHEMBL10049178 0.67 ALPL (0.72) ALPLMAPTALDH1A1LMNAMEN1
SCHEMBL23952548 0.67 ALDH1A1 (0.50) ALPLMAPTALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203044-A1 PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
US-20230203044-A1 PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
WO-2021209552-A1 PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY JANSSEN PHARMACEUTICA NV (BE) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203044-A1 PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME NLRP3, PYCARD, NLRP1 ALPL 4518/4885MAPT 1369/4885ALDH1A1 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.